



Advanced COPD Case Study

Darcy D. Marciniuk, MD FRCPC FCCP FCAHS

Professor of Respirology, Critical Care and Sleep Medicine, Royal University Hospital Associate Vice-President Research, University of Saskatchewan Saskatoon, SK, CANADA





By the end of this presentation ...

- Appreciate the realities and unmet needs of patients with Advanced COPD
- Utilize effective pharmacologic and non-pharmacologic therapies to improve symptoms and prevent acute exacerbations of COPD
- Outline a practical action plan for the optimal management and caring of advanced COPD patients, that ensures patients (and their families) receive the best care possible





Conflict of Interest Disclosure

Consultancy

Alberta Lung Association, AstraZeneca, Boehringer-Ingelheim, Canadian Foundation for Healthcare Improvement, Chinese Committee of Health and Family Planning, GlaxoSmithKline, Health Canada, Lung Association of Saskatchewan, Mylan, Novartis, Saskatchewan Ministry of Health, Saskatchewan Health Authority, Yukon Health and Social Services

Research Funding (managed by University of Saskatchewan)

AstraZeneca, Boehringer Ingelheim, Canada Health Infoway, Canadian Institute of Health Research, GlaxoSmithKline, Lung Association of Saskatchewan, Lung Health Institute of Canada, Novartis, Sanofi, Saskatchewan Health Research Foundation, Schering-Plough

Employee

University of Saskatchewan



COPD Patient Presents to the ED ...

- 76-yr-old female brought via ambulance to the ED with severe shortness of breath. Increased cough, sputum production and SOB x 6 days. Has used salbutamol MDI 30x so far today
- Diagnosed COPD 12 yrs ago, FEV₁ 23% predicted, continuous O₂
- Lives with her husband, and dependent on him
 - 55th wedding anniversary last month
- Didn't go see her family physician earlier because "the doctor is always so busy"



... in the Emergency Department

• She does not look too good!

- Initial ABGs: PaO₂ 56 mmHg; pH 7.11; PaCO₂ 97 mmHg, HCO3 43 meq/L [4 L/min O₂ via nasal prongs]
- NIV initiated, but soon thereafter becomes less responsive
- ED asks husband if they should intubate. Husband asks what does that mean, and what will happen if you don't?
 - told 'she will die' Husband says 'then intubate'





- Respiratory failure, pneumonia, hyperglycemia, impaired renal function
- Then ..., pulmonary embolism
- Then..., 'doesn't seem to be moving her left side'
- Then..., she passes away on day 8

Is there anything you would have done, or have wanted done, or not done, a little bit differently?





Clara (... 3 year earlier)

- 73-yr-old female with severe COPD
 - tiotropium (LAMA), indacaterol (LABA) and prn salbutamol (SABA)
- 3 chest infections in the past year
 - responded to antibiotics received prednisone for [only] 1
- Did not receive the influenza vaccination last year
- Tries to walk daily, but difficult too SOB, "I'm always so tired"
- CAT score: 31. 6MWD: 197 m with SpO₂ 82%
- Post-bronchodilator spirometry:

FVC (L)	2.29	70% pred	(2.4 - 4.1)
FEV ₁ (L)	0.81	36% pred	(1.7 - 2.9)
FEV ₁ /FVC	35%		(61.0 - 79.7)





More to the Story ...

- Clara states that her husband is very supportive
 - but worries how he would do if she were to die
 - "He can't cook he would starve"
- She volunteers that she would never want a machine to keep her alive, but has never discussed or shared this with her husband
 - "I'm afraid to ..."



Let's Optimize Clara's Management!

- Pharmacologic Therapy
- Non-Pharmacologic Therapies
- Prevent (or reduce the severity of) future AECOPD
- Attention to co-morbid/co-existent conditions
- Comprehensive Chronic Disease Management
- Unique Considerations for Advanced COPD






- a. Continue tiotropium and indacaterol, and add roflumilast
- b. Continue tiotropium and indacaterol, and add daily azithromycin
- **c.** Continue tiotropium, discontinue indacaterol, and add a combination inhaled corticosteroid with long-acting β2-agonist (ICS/LABA)
- d. Discontinue tiotropium and indacaterol, and switch to a combination inhaled corticosteroid with long-acting β2-agonist (ICS/LABA)



In addition to vaccination and participation in a Pulmonary Rehabilitation program, what would be the next most appropriate recommendation?

- a. Continue tiotropium and indacaterol, and add roflumilast
- b. Continue tiotropium and indacaterol, and add daily azithromycin
- c. Continue tiotropium, discontinue indacaterol, and add a combination inhaled corticosteroid with long-acting β2-agonist (ICS/LABA)
- d. Discontinue tiotropium and indacaterol, and switch to a combination inhaled corticosteroid with long-acting β2-agonist (ICS/LABA)



Adapted from Global Initiative for Chronic Obstructive Lung Disease

📚 CHEST° |

Congress

2019

Thailand

Bangkok | 10-12 April


Advanced COPD – Case Study





FOLLOW-UP PHARMACOLOGICAL TREATMENT

- 1. IF RESPONSE TO INITIAL TREATMENT IS APPROPRIATE, MAINTAIN IT.
- 2. IF NOT: ✓ Consider the predominant treatable trait to target (dyspnea or exacerbations)
 Use exacerbation pathway if both exacerbations and dyspnea need to be targeted
 ✓ Place patient in box corresponding to current treatment & follow indications
 - Access response, edjust and review
 - ✓ Assess response, adjust and review
 - \checkmark These recommendations do not depend on the ABCD assessment at diagnosis




eos = blood eosinophil count (cells/µL)

- * Consider if eos ≥ 300 or eos ≥ 100 AND ≥2 moderate exacerbations / 1 hospitalization
- ** Consider de-escalation of ICS or switch if pneumonia, inappropriate original indication or lack of response to ICS

Follow-up Pharmacologic Treatment

Global Initiative for Chronic Obstructive Lung Disease (GOLD) - 2019

COPD Pharmacotherapy





Bourbeau J, et al. Can J Resp Crit Care Med 2017; 1(4):222-241





Clara – Pulmonary Rehabilitation (8 wks)

	BEFORE	AFTER
6MWD	197 m	242 m
SGRQ	49 units	41 units
CAT	29	22

- Significant, and clinically important, improvements in walking distance and quality of life ...
 - administered rollator and supplemental O₂ with activity → additional 51 m (293 m) increase achieved





- a. Roflumilast
- b. Tele-monitoring
- c. Systemic corticosteroids
- d. Statins






a. Roflumilast

- b. Tele-monitoring
- c. Systemic corticosteroids
- d. Statins

COPD Pharmacotherapy





Bourbeau J, et al. Can J Resp Crit Care Med 2017; 1(4):222-241

Prevention of Acute Exacerbations of COPD American College of Chest Physicians and Canadian Thoracic Society Guideline

Gerard J. Criner, MD, FCCP; Jean Bourbeau, MD, FCCP; Rebecca L. Diekemper, MPH; Daniel R. Ouellette, MD, FCCP; Donna Goodridge, RN, PhD; Paul Hernandez, MDCM; Kristen Curren, MA; Meyer S. Balter, MD, FCCP; Mohit Bhutani, MD, FCCP; Pat G. Camp, PhD, PT; Bartolome R. Celli, MD, FCCP; Gail Dechman, PhD, PT; Mark T. Dransfield, MD; Stanley B. Fiel, MD, FCCP; Marilyn G. Foreman, MD, FCCP; Nicola A. Hanania, MD, FCCP; Belinda K. Ireland, MD; Nathaniel Marchetti, DO, FCCP; Darcy D. Marciniuk, MD, FCCP; Richard A. Mularski, MD, MSHS, MCR, FCCP; Joseph Ornelas, MS; Jeremy D. Road, MD; and Michael K. Stickland, PhD

BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in quality of life, need for urgent care or hospitalization, and cost of care in COPD. Research conducted over the past decade has contributed much to our current understanding of the pathogenesis and treatment of COPD. Additionally, an evolving literature has accumulated about the prevention of acute exacerbations.

METHODS: In recognition of the importance of preventing exacerbations in patients with COPD, the American College of Chest Physicians (CHEST) and Canadian Thoracic Society (CTS) joint evidence-based guideline (AECOPD Guideline) was developed to provide a practical, clinically useful document to describe the current state of knowledge regarding the prevention of acute exacerbations according to major categories of prevention therapies. Three key clinical questions developed using the PICO (population, intervention, comparator, and outcome) format addressed the prevention of acute exacerbations of COPD: nonpharmacologic therapies, inhaled therapies, and oral therapies. We used recognized document evaluation tools to assess and choose the most appropriate studies and to extract meaningful data and grade the level of evidence to support the recommendations in each PICO question in a balanced and unbiased fashion.

RESULTS: The AECOPD Guideline is unique not only for its topic, the prevention of acute exacerbations of COPD, but also for the first-in-kind partnership between two of the largest thoracic societies in North America. The CHEST Guidelines Oversight Committee in partnership with the CTS COPD Clinical Assembly launched this project with the objective that a systematic review and critical evaluation of the published literature by clinical experts and researchers in the field of COPD would lead to a series of recommendations to assist clinicians in their management of the patient with COPD.

CONCLUSIONS: This guideline is unique because it provides an up-to-date, rigorous, evidencebased analysis of current randomized controlled trial data regarding the prevention of COPD exacerbations. CHEST 2015; 147(4):894-942



Non-Pharmacologic Therapies

Recommended

- Annual influenza vaccine
- Pulmonary
 rehabilitation
 (AECOPD ≤ 4
 weeks)
- Education and case management with monthly follow-up

Suggested

- Pneumococcal vaccine
- Smoking cessation
- Education and action plan and case management

Not Suggested

- Pulmonary rehabilitation (AECOPD > 4 weeks)
- Education or case management alone
- Education with action plan but without case management
- Telemonitoring



Pharmacologic Inhaled Therapies

Recommended Suggested - LABA vs. placebo - SAMA + SABA vs. - LAMA vs. placebo SABA LABA or SAMA - SAMA + LABA vs. - ICS (LABA LABA combination) vs. - SAMA vs. SABA placebo, LABA or ICS - LABA vs. SAMA alone - LAMA/ICS/LABA - LABA vs. placebo (anticholinergic or ICS) or anticholinergic monotherapy



Pharmacologic Oral Therapies

Suggested

- Long-term macrolides
- PDE4 inhibitors
- Theophylline
- N-acetylcysteine
- Carbocysteine

- Not Recommended
- Systemic corticosteroids in an attempt to decrease AECOPD >t 30 days after initial event
 Statins





- a. Action Plan
- b. Action Plan and Education
- c. Action Plan, Education and Case Management
- d. Action Plan, Education and Tele-monitoring






- a. Action Plan
- b. Action Plan and Education

c. Action Plan, Education and Case Management

d. Action Plan, Education and Tele-monitoring





Bourbeau J, et al. Can J Resp Crit Care Med 2017; 1(4):222-241

20000 00000 00000 00000

Benefits of Education

- Provides Group Support
 Improves Self-Confidence
- Addresses Family Concerns
- Provides Disease Specific Information
- Improves Risk Factor Awareness
- Helps with Lifestyle Changes

Benefits of Exercise

Lowers Blood Pressure
 Improves Cholesterol Profile
 Assists with Weight Control
 Helps with Diabetes Prevention and Management
 Improves Quality of Life
 Decreases Stress Level
 Increases Energy Level
 Strengthens Bones

00000

Benefits of Self-management • Builds confidence

- Promotes ability to take control
 Provides practise on action planning
 Develops problem solving abilities
- Improves symptom management





CDM Program Goals

To develop and implement coordinated, effective and efficient care for people with chronic conditions

To optimize care of people by promoting a team approach and enhanced self-management of disease

To promote inter-professional collaboration and education



Optimizing Chronic Disease Management

For more information about the CDM Program, please contact:

Chronic Disease Management Program Royal University Hospital, 103 Hospital Drive Saskatoon SK S7N 0W8 Office: (306) 655-LIVE (306) 655-5483

Facsimile: (306) 655-6758 live-well@saskatoonhealthregion.ca



Live

Chronic Disease Management Program

Optimizing Chronic Disease Management

00000



Group ExerciseDisease-SpecificPatient Self-and RehabilitationManagementManagement

- Communitybased exercise and rehabilitation programming
- Group education
- Group and social support

Interprofessional team working with the patient, family, and Family Physician

 Evidence-based optimal care delivery

- Individualized plan of action
- Patient-led group support "LiveWell with Chronic Conditions"
- Enhanced selfmanagement skills



Optimizing Chronic Disease Management



Patient Benefits and Outcomes

- Improved exercise tolerance (64 m in 6MWD)
- Improved quality of life
 - SGRQ reduced by 8.3 (52.9 to 44.6) at 3 months, 5.6 at 6 months, 5.3 at 1 year
- Decreased healthcare utilization:
 - COPD re-admissions reduced by 71%, hospital days by 62%, ER visits by 44% at 1 year
 - 3 year follow-up: COPD re-admissions reduced by 64%, hospital days by 29%, ER visits by 30%
- Improved quality of life, enhanced exercise tolerance, reduced exacerbations and hospitalizations, <u>and</u> reduced healthcare costs ('costdominant').



Specific triggers that should prompt Advanced Care Planning (ACP) discussions include which of the following?

- a. $FEV_1 < 30\%$ predicted
- b. Oxygen dependence
- c. ≥ 1 hospital admissions in prior year for AECOPD
- d. Decreased functional status, and weight loss/cachexia
- e. All of the above



Specific triggers that should prompt Advanced Care Planning (ACP) discussions include which of the following?

- a. FEV₁ <30% predicted
- b. Oxygen dependence
- c. ≥ 1 hospital admissions in prior year for AECOPD
- d. Decreased functional status, and weight loss/cachexia

e. All of the above





- Poor functional status (MRC 5)
- Severe acute exacerbation(s)
- **FEV₁** < 30-40% predicted
- Signs of pulmonary hypertension
- Respiratory failure with CO₂ retention
- Body mass index < 20 kg/m²
- Patient is starting to wish for or talk about death
- "Dying this year would not be a surprise"



'Quality' Advanced and EOL Care

- Timely, accurate and open communication
 - what they want, and what they do not want ...
 - assure the patient that no decision is 'final'
- Appropriate symptom control
 - dyspnea, fear, pain, depression, anxiety, ...
- Continuity of care
- Patient and family satisfaction with care
- Minimal caregiver burden
- 'Best' quality of life during the time patient is living with advanced COPD
 - as judged by the patient and family

Goodridge DM, et al. National Consensus Recommendations. Can Resp J 2009; 16:e51-e53



So Let's Get Back To Clara ...

Optimal pharmacologic and non-pharmacologic management

- including pulmonary rehabilitation, rollator with activity, vaccinations
- Early intervention with appropriate recognition and treatment of AECOPD, and active management to prevent future AECOPD
- Effective case-management of this patient's advanced disease
- Earlier and open discussions regarding advanced care planning
 - severity of disease, potential outcomes/options, patient/family wishes
 - assist the patient and family to be 'best-informed'



... in the Critical Care Unit

- Respiratory failure, pneumonia, hyperglycemia, impaired renal function
- Then ..., pulmonary embolism
- Then..., 'doesn't seem to be moving her left side'
- Then..., she passes away on day 8

Is there anything you would have done, or have wanted done, or not done, a little bit differently?



